In Table 3, the HRs for diabetes and ERG-negative and ERG-positive prostate cancers were 0.63 (0.42–0.95) and 0.72 (0.46–1.12); and for PTEN-intact and PTEN-loss prostate cancer were 0.69 (0.48–0.98) and 0.52 (0.19–1.41), respectively. This evidence concerns the gene ERG and prostate cancer.